复星医药(02196)拟新增控股子公司复星医药(深圳)作为“FS-1502”的实施主体之一
复星医药(02196)发布公告，根据集团内部分工及管理需要，拟新增控股子公司复星医药(深圳)作为2022年非公开发行募投项目“创新药物临床、许可引进及产品上市相关准备”之子项目“FS-1502”的实施主体之一。本次新增实施主体后，将由复星医药产业(同为公司控股子公司)、复星医药(深圳)共同作为子项目“FS-1502”的实施主体。由于复星医药(深圳)非本次发行募投项目的原实施主体，上述调整构成新增募投项目实施主体。
公告称，本次新增实施主体系结合集团内部分工及管理之需要，未改变募集资金的用途、投向和投资金额。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.